Background: Despite the significant clinical benefits of betablockers in heart failure with reduced ejection fraction (HFrEF), prescription for and adherence to these agents is reported to be poor. There are few data on the use and tolerance of beta-blocker therapy in patients with HFrEF in South Africa and it is unknown whether these patients would benefit from further heart rate-lowering therapy. Methods: Data from all patients with HFrEF attending the heart failure clinic of Charlotte Maxeke Johannesburg Academic Hospital from January 2000 to December 2014 were retrospectively collected. We first determined the rates of beta-blocker intolerance in this population and then categorised the patients according to their most recent dose of betablocker (low, moderate or target dose) in order to identify factors associated with beta-blocker intolerance. Lastly, we used the data to identify patients who would be suitable for further treatment with heart rate-lowering therapy. Results: Five hundred patients, with a median follow up of 58.7 months, were identified during the study period. Black South Africans constituted the majority (66.4%) and most patients had HFrEF due to hypertension (32.8%). At the last recorded clinic visit at the end of the study period, 489 patients (97.8%) were taking a beta-blocker with 59.8% prescribed a beta-blocker at target dose. Consistent with previous data, bradycardia was the commonest cause for failing to reach target beta-blocker dose. Only 61 (12%) patients were on no (n = 11) or low (n = 50) dose of beta-blocker at final clinic visit. As per current guidelines, only 10.6% (n = 53) of this cohort of patients would qualify for further treatment with heart rate-lowering therapy.
The benefit of beta-blockers in chronic heart failure is well established. 1 Major clinical trials have consistently shown reduced rates of morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF) when beta-blockers are included in the treatment regimen. [2] [3] [4] [5] [6] As a result, beta-blockers have become an established first-line, best-practice treatment in the management of HFrEF, as reflected in the guidelines of major national and international cardiology organisations such as the American Heart Association (AHA)/American College of Cardiology (ACC) and European Society of Cardiology (ESC) (adopted with minor modification by the Heart Failure Society of South Africa, a special-interest group of the South African Heart Association). [7] [8] [9] Despite the documented survival benefit, the percentage of patients achieving target doses, as recommended in the guidelines, is relatively poor. [10] [11] [12] For example, only 39% of patients with primary prevention implantable cardioverter defibrillators for cardiomyopathy were on ≥ 50 mg of carvedilol in a recent Danish registry study. 13 Numerous reviews and surveys have shown that beta-blockers have been under-used and under-dosed in heart failure patients for various reasons, 14 with only 20 to 40% of heart failure patients tolerating beta-blockers at target doses, and the mean doses found to be only half the recommended target dose. 10 Patients outside of large protocol-driven clinical trials consistently failed to achieve target dose and/or target heart rate, with surveyed physicians often reluctant to initiate or up-titrate beta-blockers appropriately because of concerns about safety and tolerability. 14 In light of the documented adverse effect on mortality of an elevated heart rate, the demonstration of mortality benefit in heart rate-reduction therapy, and the reluctance of physicians to adequately prescribe and up-titrate beta-blockers at target dose due to safety concerns, a pure heart rate-lowering agent was sought. 15 Ivabradine, a selective I f current inhibitor, induces dose-dependent heart rate reduction by directly reducing sinoatrial node pacemaker activity. This agent has been studied in the seminal SHIFT trial (Systolic Heart failure treatment with I(f) inhibitor ivabradine Trial), 16, 17 where 6 558 patients with chronic heart failure, left ventricular ejection fraction < 35%, and a baseline heart rate (HR) > 70 beats per minute were randomised to receive ivabradine or placebo. Patients were already meant to be on optimal guideline-directed heart failure therapy (including beta-blockers at maximally tolerated doses).
There is a paucity of data in South African patients regarding the need for further heart rate-reduction therapy in patients with HFrEF. It is our hypothesis that most heart failure patients tolerate guideline-mandated doses of beta-blocker therapy and, if adequately up-titrated, will not need further rate reduction with agents such as ivabradine. We therefore sought to investigate target dosing and tolerability of beta-blockers in a heart failure population at a tertiary public hospital in Johannesburg, South Africa, in order to determine the need for additional heart ratelowering agents.
Methods
Ethical approval for our study was obtained from the Human Research Ethics Committee, University of the Witwatersrand. Clinical records of all patients attending the Heart Failure Clinic at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in the period January 2000 to December 2014 were retrospectively reviewed.
Files for all adult patients who attended the heart failure clinic at CMJAH during this period were included. Data were extracted from every file, even from those who had died, since our focus was the dose of beta-blocker at their last visit. These patients were referred to this specialist clinic with a diagnosis of HFrEF (patients with heart failure due to other aetiologies, such as valvular heart disease, do not attend the clinic), diagnosed by a clinician at CMJAH or a referral hospital and confirmed by transthoracic echocardiography demonstrating left ventricular ejection fraction (LVEF) < 50%. Demographic and clinical data at first clinic appointment and at the last visit were recorded.
Patients were then categorised according to their beta-blocker dosing at their last visit in order to determine the rates of betablocker tolerance within this population and to identify factors related to beta-blocker tolerance. Patients were categorised into low-, moderate-and target-dose categories based on target dosing in major trials (Table 1) . 18 Since some patients had access to atenolol only, and no target dose exists for atenolol in heart failure, dosing was based on standard dosing in systemic hypertension.
Statistical analysis
Descriptive statistical methods were used. Continuous variables are expressed as means ± standard deviations (SD) for normally distributed data or medians with interquartile ranges (IQR) for non-parametric data; p-values were calculated using the paired t-test. Data were analysed using SPSS Statistics ® (version 22) and p-values < 0.05 were considered to be significant.
Results
Five hundred patients fulfilled the inclusion criteria for the study and were included in this analysis. Patients in the clinic Table 1 . Categorisation according to beta-blocker dosage (total daily dose)
Beta-blocker Low dose (mg) Moderate dose (mg) Target dose (mg)
Bisoprolol < 5 5 to < 10 10 Carvedilol < 25 24 to < 50 50
Metoprolol < 100 100 to < 400 400
Atenolol < 50 40 to < 100 100 HF = heart failure; IHD = ischaemic heart disease; HT = hypertension; PPCMO = peripartum cardiomyopathy; HIV = human immunodeficiency virus; NYHA = New York Heart Association classification; eGFR = estimated glomerular filtration rate; SBP = systolic blood pressure; HR = heart rate; BPM = beats per minute; ACEI = angiotensin converting enzyme inhibitor; MRA = mineralocorticoid receptor antagonist; ISMO = isosorbide mononitrate; CCB = calcium channel blocker; NA = not applicable.
were managed according to local and international best practice. Beta-blockers were routinely used and judiciously up-titrated to target doses, as tolerated. Baseline characteristics are shown in Table 2 . Male patients comprised 52.5% (n = 263) and the mean (SD) age of the cohort was 55 (15) years. Black patients (66.4%) constituted the predominant ethnic group of the study. Hypertensive heart disease was the commonest cause of heart failure (32.8%), followed by ischaemic heart disease (22%). Mean (SD) LVEF at admission to the clinic was 27.3% (8.36 ).
Median follow-up duration (first appointment recorded at clinic to last recorded visit) was 58.7 months (IQR 25-86). At enrolment, 87% of patients (n = 436) were in sinus rhythm. Mean (SD) initial heart rate was 85.9 (15.4) beats per minute (bpm), with last achieved mean heart rate 71.7 (11.0) bpm. The majority of patients were on guideline-recommended heart failure therapy. For example, 95.8% of patients were prescribed angiotensin converting enzyme (ACE) inhibitors and 89.8% were prescribed spironolactone (Table 2) .
At their last clinic visit, 489 patients (97.8%) were prescribed and tolerating a beta-blocker. Patients were stratified into categories according to target doses of beta-blocker achieved (Table 1) . Twenty-six patients (5%) were on atenolol, as they collected their prescriptions from peripheral clinics where this was the only beta-blocker available to them. Carvedilol was used by 463 (92.6%) patients, while none were on metoprolol or bisoprolol because these were not available in CMJAH during the study period.
In 59.8% (n = 299) of patients a target dose was achieved, while in 28.0% (n = 140) a moderate dose was achieved, and only 5.4% (n = 50) of patients received a low dose of beta-blockers (Fig. 1) . Reasons for intolerance, defined as no or low doses (< 50% of target dose), and reasons for not achieving target dose are detailed in Table 3 . Conventional reasons for clinician betablocker caution, such as bronchospasm or breathlessness (n = 7; 1.4%), peripheral arterial disease (n = 0), syncope (n = 3; 0.6%), cardiac decompensation (n = 4; 0.8%) and hypotension (n = 2; 0.2%) were uncommon.
Of patients who were not at target beta-blocker dose, approximately 10% were still in the up-titration phase at the end of the study period, while in 5% (n = 25) no reason was determined. Bradycardia was the most common reason for lack of up-titration to target dose. Of the 201 patients who did not achieve target dosing, 51.7% were at target heart rates. Patients on beta-blocker at the end of the study period were categorised into 'low' , 'moderate' or 'target' dose of beta-blocker therapy. Patients who were on only a low dose of beta-blocker therapy or no beta-blocker therapy were termed 'beta-blocker intolerant' . HFrEF: heart failure with reduced ejection fraction. BB: beta-blocker. Patients with heart failure due to impaired left ventricular function (LVEF < 50%) constituted the entire study population. Of the 500 patients with heart failure and reduced EF, only 53 would have qualified for further heart rate-reduction therapy with ivabradine on the basis of being in sinus rhythm, having a LVEF < 35%, having a heart rate of > 70 bpm and being in NYHA class II-IV heart failure. LV: left ventricular; EF: ejection fraction. There were no statistically significant correlates for intolerance in terms of ethnicity, cause of heart failure or presence or absence of concurrent treatments. A history of asthma (p = 0.021) and a diagnosis of hypothyroidism (p = 0.009) were independently correlated with beta-blocker intolerance.
Patients were deemed to be ivabadrine 'suitable' if they were in sinus rhythm, with a LVEF < 35% and a resting heart rate of ≥ 70 bpm after appropriate up-titration of a beta-blocker. 7 Of the 500 patients who were initially assessed, 137 met this criterion (27.4%). After excluding patients with New York Heart Association class I symptoms, only 53 (10.6%) were deemed to be ivabadrine suitable (Fig. 2) .
The ivabadrine-suitable subgroup at enrolment had a lower mean ejection fraction compared to the larger clinic cohort (LVEF: 20.9 vs 27.3%, p = 0.0001), as well as higher resting heart rates (mean 94.2 vs mean 85.9 bpm, p = 0.006). In addition, this subgroup had a shorter follow-up duration (43.3 vs 58.7 months, p = 0.006). Diabetes mellitus correlated with ivabadrine suitability (p = 0.003), with these patients being twice as likely to meet the criteria for ivabradine suitability. Not patient gender, cause of heart failure, or associated treatments was statistically associated with meeting the criteria for ivabradine therapy.
Discussion
Efficacy of beta-blockers in patients with HFrEF is well established. However, actual use has been unsatisfactory, largely due to perceptions about tolerability and consequent reluctance among clinicians to up-titrate doses despite guideline recommendations. 5 Unfortunately, the perceptions of danger and intolerability of beta-blockers appear to be over-exaggerated by many physicians, to the disadvantage of patients who would benefit. 19, 20 In this study, we have demonstrated that in a dedicated heart failure clinic in a large urban public hospital in Johannesburg, South Africa, the majority (97.8%) of HFrEF patients could be prescribed a beta-blocker. In contrast to large international surveys, we found that beta-blockers were generally well tolerated by patients attending the heart failure clinic. Almost 88% of these patients tolerated up-titration of their beta-blocker to target or moderate target doses. In this real-world population, we have shown that beta-blockers were used more often and at much higher doses than those reported in multi-centre surveys and registries in other parts of the world.
11,13
Furthermore, we have shown that in certain subgroups of patients with co-morbid diseases, such as chronic obstructive pulmonary disease, diabetes and peripheral arterial disease in whom beta-blocker usage by clinicians is historically poor, the use of beta-blockers is generally safe, with a small minority unable to tolerate target doses. The only statistically significant predictors for beta-blocker intolerance were concurrent asthma (but not chronic obstructive pulmonary disease) and hypothyroidism. Bradycardia was the commonest reason for patients not being at target betablocker dosage, which is consistent with previously reported data. 20 In the South African context, there are few published data regarding beta-blocker use, tolerability and achievement of target doses in chronic heart failure patients. In low-and middleincome countries, it has been reported that only 34% of heart failure patients receive beta-blocker therapy. 21 In the Heart of Soweto Study cohort, 64% of patients received a beta-blocker during the index admission for acute heart failure, 22 while in a study in Cape Town the rate of beta-blocker use at the time of discharge after an acute heart failure episode was only 42.7%. 23 However, data on out-patient beta-blocker use is lacking, particularly in black patients, a group that has historically been under-represented in major heart failure trials.
In the current study, black patients constituted 66% of the cohort, whereas in the SHIFT study, 8 similar to most international trials, the majority of patients were white (89%), with black patients comprising less than 3% (grouped in category of 'other'). Although lacking specific data, it would appear that the socio-economic status of our cohort of patients attending a public hospital was substantially different from that of patients enrolled in the large European and North American clinical trials. Yet, despite the challenges of this relatively economically poor group of patients, the majority of patients were able to be compliant and were up-titrated successfully.
Our data also suggest that the role for additional ratecontrol therapy beyond beta-blockers in systolic heart failure patients is limited to only a small group of selected patients. Although SHIFT 17 reported that heart rate reduction with ivabradine reduced the composite end-point of mortality and cardiovascular-associated hospitalisation was reduced by 18%, background beta-blocker usage was substantially lower in the trial population than would have been clinically expected by the very clear guideline recommendation for patients with HFrEF.
In the SHIFT study, only 23% of the patients were at target doses, and less than half (49%) were receiving 50% or more of the target doses at enrolment. The authors of the study explained that the low beta-blocker dose and frequency of use was a result of standard clinical practice in their large study population. However, criticism of applicability followed, since under-treatment with beta-blockers could have inflated the potential benefit and exaggerated the proposed role of ivabradine as a treatment modality. 24, 25 Despite the criticism, use of ivabradine has been given a class IIa recommendation for the reduction of hospitalisation or cardiovascular death in the latest ESC heart failure guidelines. 7 The patient population studied in SHIFT was broadly similar to our cohort but there are a number of notable differences. In our study, patients were younger by five years (mean age 55.8 vs 60.1 years), included more females (47 vs 24%), and were more ethnically diverse. Ischaemic heart disease was the predominant cause of heart failure in SHIFT (68%), compared with 22% in our study. LVEF at enrolment was slightly worse in our study patients compared with the SHIFT population (27 vs 29%). Mean estimated glomerular filtration rate (eGFR, ml/min per 1.73 m 2 ) in our study patients was better (85.2 ml/min) compared with the SHIFT cohort (74.6 ml/min).
These and possibly other unmeasured factors may have played a role in the better response and tolerance of our patients to beta-blockade. Despite these differences, our data suggest that the findings of SHIFT (that beta-blocker intolerability is a major indication for use of pure heart rate-reducing agents) are not wholly applicable in our setting.
This study has some limitations. Selection and information bias are known limitations in retrospective studies. Furthermore, this was a single-centre study in a dedicated heart failure clinic, which may mean that the findings may not be generally applicable in less dedicated facilities and in other regions.
Conclusion
This study demonstrates that in a public hospital in South Africa, a concerted strategy to initiate and progressively up-titrate beta-blockers in patients with HFrEF was highly successful in the majority of patients. Furthermore, beta-blockers were found to be well-tolerated in this group of patients. Our results suggest that the number of patients in South Africa who may qualify for further heart rate-reduction therapy would be small after deliberate efforts to initiate and up-titrate beta-blockers, according to local and international standards.
